money moves

Houston blockchain startup closes $3 million seed led by local VC

Mercury Fund led Topl's $3 million seed round. Photo via Getty Images

A Houston-based blockchain company that focuses on providing companies with ethical and sustainable practices within the supply chain has closed a $3 million round with support from investors both locally and across the country.

Today, Topl announced the closing of its seed round, which was led by Houston-based Mercury Fund with support from Houston-based GOOSE Capital, Chicago-based Chingona Ventures, Dallas-based RevTech Ventures, and New York-based firms Beni Venture Capital, Blue Collective, and Social Impact Capital.

"We're grateful to have closed an oversubscribed venture round during a pandemic, especially given the unfortunate truth that many women-led startups are getting much less investment during this time," says Kim Raath, CEO of Topl, in a press release. "Bringing transparency to causes dedicated to environmental and social good has never been more important. We are building a modern blockchain for a world where purpose and profit go hand in hand."

According to the release, Topl will use the fresh funds to speed up the launch of the company's blockchain-as-a-service solution for early next year.

Earlier this month, Topl announced a partnership with Denver-based TrackX, a software-as-a-service asset management and supply chain solution provider, aimed at combining technology to create a verifiable tracking and tracing solution to equip company supply chains with sustainability, transparency, and efficiency. Ultimately, it's Topl's goal to allow its users the ability to stand out to customers as sustainable and responsible brands — something that's become increasingly more important to consumers.

"A company's social and environmental impact has become a necessary point of differentiation for brands, and Topl has the potential to be the leading player for brands who are serious about [Environmental, Social, and Corporate Governance]," says Blair Garrou, managing director of Mercury Fund.

To date, Topl has raised $4.4 million in funding. It's first seed round closed September 2019. For that round, Samantha Lewis, formerly director of GOOSE Capital, was instrumental, according to the release.

"Kim and the Topl team have created a custom-designed method to measure and verify your company's sustainability efforts. We're excited to be part of this intersection of cutting-edge technology and positive impact," Lewis, who's now on the board of the startup, says in the release.

Topl's technology has the ability to affect any industry, and the company has worked with tracing products from diamonds and chocolate to natural resources and even COVID-19 testing.

"Topl's track-and-trace solution appeals to so many core industries: from healthcare to agriculture to energy," says Manolo Sánchez, former chairman and CEO of BBVA Compass and also a member of Topl's board, in the release. "Anyone who needs to ensure transparency, efficiency and sustainability would benefit from their technology."

Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News